YD Bio Ltd (YDES) Stock Analysis
Verdict: AVOID
Severe cash burn and potential dilution offset early-stage exosome biotech ops — cash runway under 9 months.
Investment score: 19/100
Analysis as of
Is YD Bio Ltd stock worth reviewing? AI model thesis
The AI model views YDES as a high-risk speculative biotech burdened by negative equity (-$2.86M) and under 9 months of cash runway based on 2025 FCF burn of -$8.04M.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
YD Bio Ltd opportunities and risks
What speaks for YDES
- Proprietary Exosome Diagnostic Platform
What speaks against YDES
- Insolvent Balance Sheet with Under 9 Months Cash Runway
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| YDES | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.3% |
| MENS | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
Frequently asked questions about YD Bio Ltd (YDES)
Is YDES stock a good investment?
The cached TradeMates AI model rates YD Bio Ltd as AVOID with an investment score of 19/100. The AI model views YDES as a high-risk speculative biotech burdened by negative equity (-$2.86M) and under 9 months of cash runway based on 2025 FCF burn of -$8.04M. This is algorithmic model output, not personal investment advice.
Is YDES stock a buy?
The TradeMates model verdict for YDES is AVOID with an investment score of 19/100. Treat this as a model signal to review, not a personal buy recommendation.